The Phase 3 TANGENT trial showed that emactuzumab significantly improves outcomes for patients with tenosynovial giant cell tumor compared to placebo. At six months, patients receiving the drug had higher tumor response rates and greater reductions in tumor size. Many also experienced quick and lasting improvements in physical function, including less pain, better movement, and reduced stiffness.
The treatment offers a different approach from current therapies. Instead of long-term daily oral medication, emactuzumab is given as a short 10-week course of five intravenous infusions. It works by targeting tumor-associated macrophages and triggering their death, addressing the root cause of the disease. This shorter regimen could reduce the burden of ongoing treatment for patients.
Safety results were consistent with earlier studies, with no new concerns reported. Common side effects included itching and facial swelling. The therapy received FDA Fast Track designation in 2025, and a regulatory filing is planned for 2026, with further studies ongoing to assess long-term benefits.